Clinical significance of plasma D-dimer detection in patients with non-small cell lung cancer

doi:10.3969/j.issn.1673-8640.2015.04.005

Abstract

Abstract:

Objective To investigate the clinical value of the plasma D-dimer detection in patients with non-small cell lung cancer(NSCLC). Methods The plasma D-dimer levels of 47 NSCLC patients and 66 healthy subjects were detected by immuno-nephelometry. The relationships between plasma D-dimer level and the clinical stage, pathological type and lymph node metastasis of NSCLC patients were analyzed.The D-dimer levels of NSCLC patients before and after chemotherapy were compared. The relationship between the D-dimer and the efficacy of chemotherapy was analyzed. Results The levels of plasma D-dimer were significantly higher in NSCLC patients[0.96(0.63~1.35)mg/L] than in the healthy subjects[0.34(0.17~0.39)mg/L,P<0.01]. The levels of plasma D-dimer in different clinical stage groups and pathological type groups were statistically significant(P<0.05);and it had relationship with lymph node metastasis(r=0.609, P<0.05). After chemotherapy, the levels of D-dimer in effective groups(contain complete response group and partial response group)were significantly decreased(P<0.05). There were no significant changes in stability group(P>0.05)and significant higher in progress group(P<0.05). Conclusions The plasma D-dimer has clinical significance in the clinical stage, pathological type and lymph node metastasis in NSCLC patients, and can be used as an effective indicator to evaluate the efficacy of chemotherapy.

Key words: D-dimer, Non-small cell lung cancer, Chemotherapy

CLC Number:

R446.11

SHEN Wang, LING Shoujian, YE Liyan, YANG Wenli, TAN Xiaoyu. Clinical significance of plasma D-dimer detection in patients with non-small cell lung cancer[J]. Laboratory Medicine, 2015, 30(4): 318-320.

Figures/Tables 2

References 10

[1]	师越,张俊,陈鹏. 血清胰岛素样生长因子-1检测在非小细胞肺癌早期诊断中的应用价值[J]. 检验医学,2013,28(6):503-505.
[2]	吴利,周才,黄瑞玉,等. 正常孕妇血浆D-二聚体的检测和分析[J]. 检验医学,2014,29(10):992-994.
[3]	DIAO D,ZHU K,WANG Z,et al.Prognosis value of the D-dimer test in oesophageal cancer during the perioperative period[J]. J Surg Oncol,2013,108(1):34-41.
[4]	FERRONI P,MARTINI F,PORTARENAL I,et al.Novel high-sensitive D-dimer determination predicts chemotherapy-associated venous thromboembolism in intermediate risk lung cancer patients[J]. Clin Lung Cancer,2012,13(6):482-487.
[5]	邓淑萍,勒建军,田蕊,等. 肺癌患者血浆D-二聚体、纤维蛋白原水平分析[J]. 国际呼吸杂志,2014,36(12):922-925.
[6]	CAVALIERE L.Thromboprophylaxis in ambulatory lung cancer treatment[J]. Clin J Oncol Nurs,2013,17(1):74-79.
[7]	HOLMES HM,BAIN KT,ZALPOUR A,et al.Predictors of anticoagulation in hospice patients with lung cancer[J]. Cancer,2010,116(20):4817-4824.
[8]	张平平,孙军伟,卢久琴,等. 非小细胞肺癌患者的基线D-二聚体水平与预后的关系[J]. 中华肿瘤杂志,2013,35(10):747-750.
[9]	GIESELER F,LUHR I,KUNZE T,et al.Activated coagulation factors in human malignant effusions and their contribution to cancer cell metastasis and therapy[J]. Thromb Haemost,2007,97(6):1023-1030.
[10]	沈宏远,王妍,黄红宇,等. 非小细胞肺癌患者血浆D-二聚体水平对预后评估的意义[J]. 临床检验杂志,2014,32(4):259-261.

组别	例数	D-二聚体	腺癌		鳞癌
组别	例数	D-二聚体	例数	D-二聚体	例数	D-二聚体
健康对照组	66	0.34(0.17~0.39)
NSCLC组	47	0.96(0.63~1.35)^*	27	0.99(0.76~1.36)	20	0.86(0.64~1.10)^□
Ⅰ期	10	0.65(0.49~0.84)^*	6	0.67(0.56~0.85)	4	0.51(0.44~0.79)
Ⅱ期	15	0.85(0.65~1.09)^*#	9	0.94(0.80~1.12)	6	0.72(0.61~0.89)^□
Ⅲ期	14	1.14(0.87~1.44)^*#△	8	1.27(1.01~1.46)	6	0.99(0.84~1.17)^□
Ⅳ期	8	1.68(1.47~1.89)^*#△▲	4	1.78(1.64~2.00)	4	1.31(1.01~1.73)^□

组别	例数	D-二聚体	腺癌		鳞癌
组别	例数	D-二聚体	例数	D-二聚体	例数	D-二聚体
健康对照组	66	0.34(0.17~0.39)
NSCLC组	47	0.96(0.63~1.35)^*	27	0.99(0.76~1.36)	20	0.86(0.64~1.10)^□
Ⅰ期	10	0.65(0.49~0.84)^*	6	0.67(0.56~0.85)	4	0.51(0.44~0.79)
Ⅱ期	15	0.85(0.65~1.09)^*#	9	0.94(0.80~1.12)	6	0.72(0.61~0.89)^□
Ⅲ期	14	1.14(0.87~1.44)^*#△	8	1.27(1.01~1.46)	6	0.99(0.84~1.17)^□
Ⅳ期	8	1.68(1.47~1.89)^*#△▲	4	1.78(1.64~2.00)	4	1.31(1.01~1.73)^□

化疗疗效	例数	D-二聚体(mg/L)		Z值	P值
化疗疗效	例数	治疗前		Z值	治疗后
完全缓解组	11	0.68(0.51~0.99)	0.37(0.31~0.52)	-3.196	0.001
部分缓解组	15	0.88(0.67~1.18)	0.65(0.45~0.91)	-2.805	0.007
稳定组	14	0.97(0.80~1.33)	0.91(0.22~1.20)	-2.012	0.055
进展组	7	1.63(1.42~1.89)	2.08(1.78~2.39)	-2.657	0.016

化疗疗效	例数	D-二聚体(mg/L)		Z值	P值
化疗疗效	例数	治疗前		Z值	治疗后
完全缓解组	11	0.68(0.51~0.99)	0.37(0.31~0.52)	-3.196	0.001
部分缓解组	15	0.88(0.67~1.18)	0.65(0.45~0.91)	-2.805	0.007
稳定组	14	0.97(0.80~1.33)	0.91(0.22~1.20)	-2.012	0.055
进展组	7	1.63(1.42~1.89)	2.08(1.78~2.39)	-2.657	0.016

[1]	ZHOU Yunlan, SHEN Lisong. Clinical application and challenges of liquid biopsy biomarkers in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(9): 807-811.
[2]	CHEN Ying, LI Wei, LIN Tao, YANG Li. Relationship between PFTK1 expression level and microvessel density and postoperative prognosis in non-small cell lung cancer [J]. Laboratory Medicine, 2023, 38(7): 634-639.
[3]	YUAN Shuang, FENG Lei, GUO Xiaofen, FU Xiaoling, XU Jing, LIU Hongyang. Relation of miR-433 in endometrial cancer tissues and its relationship with chemotherapy sensitivity [J]. Laboratory Medicine, 2023, 38(4): 337-341.
[4]	YANG Zhongxin, LI Xiaoyu, CHEN Tao, CAO Wenjun. Roles of IL-8 and MMP-2 in the prognosis of non-small cell lung cancer patients after thoracoscopic segmentectomy [J]. Laboratory Medicine, 2023, 38(4): 342-346.
[5]	SONG Shiwei, LI Jingwu, LIN Tao, LIU Zeyu, WANG Zhiqiang, SUN Weidong. Relationship between GPNMB and non-small cell lung cancer immune infiltration and prognosis [J]. Laboratory Medicine, 2023, 38(4): 347-351.
[6]	CHEN Zhe, ZHANG Ling, LIU Jie, WANG Xia, ZHANG Bin, GAO Binghua. Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy [J]. Laboratory Medicine, 2023, 38(3): 251-256.
[7]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[8]	GAO Jianchao, WANG Sisi, ZHANG Zhisheng, ZHANG Jingli, LI Xiaoxia, MA Ke, FENG Zhilin, ZHOU Haifeng, WANG Zhanhai. Efficacy and prognosis evaluation of neo-adjuvant chemotherapy for breast cancer based on miR-206，miR-125 and miR-21 [J]. Laboratory Medicine, 2023, 38(11): 1062-1068.
[9]	WEN Jing, SHI Rui, XIE Jia, LIU Feng, LI Guang, REN Jingjing, LEI Xiaoru, GUO Xiaobo, SONG Yanping. Clinical application of metagenomic next-generation sequencing for determining pathogens in febrile neutropenic patients [J]. Laboratory Medicine, 2022, 37(9): 855-859.
[10]	LIANG Chunfang, ZHU Kangning, ZHANG Qi. Serum miR-21 and miR-135a expression levels in predicting the recurrence and metastasis of gastric cancer patients after chemotherapy [J]. Laboratory Medicine, 2022, 37(5): 417-422.
[11]	GAO Feng. Research progress of new tumor molecular markers in the age of precision medicine：from accurate diagnosis to precision chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 309-312.
[12]	ZHAO Mingna, ZHANG Chenzi, HONG Qiushuang, LOU Jiatao. Mechanism of IL-8/miR-182 positive feedback regulatory axis in non-small cell lung cancer [J]. Laboratory Medicine, 2022, 37(4): 349-355.
[13]	WANG Jianying, WANG Shanshan, ZHU Jun, HUANG Xiaochun, WAN Yuxiang, LIU Yun. Distribution and drug resistance of respiratory infection pathogens in patients with lung cancer after chemotherapy [J]. Laboratory Medicine, 2022, 37(4): 356-359.
[14]	XU Runhao, ZOU Chen, CAO Yun, CHEN Feng, LIU Yijing, ZHANG Shulin, ZHANG Jie. Roles of serum amino acid determinations in the diagnosis of early non-small-cell lung cancer [J]. Laboratory Medicine, 2022, 37(12): 1157-1163.
[15]	MAN Xianfeng, HE Xiaoting, ZHANG Ying, YU Weiwei, WANG Qi, YIN Hanwei, WANG Runjie. Application of thioredoxin reductase in monitoring the curative effect of lung cancer [J]. Laboratory Medicine, 2022, 37(1): 56-59.